Unfortunately some errors appeared in this paper.

In Table 1, ‘Potential decrease MIb’ should have appeared as an Advantage, not Disadvantage, for Thiazolidinediones (glitazones).

In Figure 1, the footnote for ‘Intensive insulin + metformin ± glitazone’ should have been b not c.

In the Discussion, the sentence: ‘These findings have led to a stronger (black box) warning in the prescribing information for the thiazolidinediones [15]’ should have read:

‘These findings have led to a stronger ‘black box’ warning in the prescribing information for rosiglitazone regarding the risk for myocardial infarction and for both thiazolidinediones regarding the risk for CHF [15]’.

Reference 15: The website was last accessed on 17 November 2007, not 25 October 2007.